Global Panic Attack Treatment Market

Panic Attack Treatment Comprehensive Study by Type (Spontaneous Panic Attacks, Situationally Bound Panic Attacks, Situationally Predisposed Panic Attacks), End Users (Adults, Children and Adolescents, Specific Populations), Treatment Type (Therapy (Cognitive Behavioral Therapy (CBT), Exposure Therapy, Relaxation Techniques), Medication (Antidepressants, Benzodiazepines)), Indicators (MDD, OCD, Phobia) Players and Region - Global Market Outlook to 2029

Panic Attack Treatment Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Panic Attack Treatment
Panic attacks are sudden, intense feelings of fear that cause physical symptoms like a racing heart, fast breathing and sweating. Some people who experience panic attacks develop panic disorder, a type of anxiety disorder. Therapy and medications can treat panic attacks and panic disorder.. According to World Health Organization (WHO) Fact Sheet, depression is a “common illness worldwide, with more than 300 million 51 people affected. Panic attack treatment is the type of treatment for Selective serotonin reuptake inhibitors (SSRIs). Panic attack and anxiety attack are the two different attacks. Panic attacks are unprovoked and unpredictable. Yoga and deep breathing may help to reduce incidences of panic attack. There are various symptoms of panic attack such as sweating, trembling, shortness of breath, a choking sensation, chest pain, nausea, dizziness, fear of losing your mind, fear of dying, feeling hot or cold and numbness or tingling. These type of attacks are happens anywhere and anytime.

AttributesDetails
Study Period2018-2029
Base Year2023
UnitValue (USD Million)


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Panic Attack Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer Inc. (United States), GlaxoSmithKline (United Kingdom), Merck & Co. Inc. (United States), Sanofi-Aventis (France), AstraZeneca (United Kingdom), Eli Lilly and Company (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), F-Hoffmann-La Roche (Switzerland) and Shionogi and Company (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Forest Laboratories Inc. (United States), H. Lundbeck A/S (Denmark), Allergan Plc. (Ireland), GlaxoSmithKline Plc. (United Kingdom), Sumitomo Dainippon Pharma Co., Ltd. (Japan), Bristol-Myers Squibb Company (United States) and Noven Pharmaceuticals, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Panic Attack Treatment market by Type (Spontaneous Panic Attacks, Situationally Bound Panic Attacks and Situationally Predisposed Panic Attacks) and Region.



On the basis of geography, the market of Panic Attack Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Adults will boost the Panic Attack Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Therapy (Cognitive Behavioral Therapy (CBT), Exposure Therapy, Relaxation Techniques) will boost the Panic Attack Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indicators, the sub-segment i.e. MDD will boost the Panic Attack Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emergence of Comparatively more Effective and Efficient Panic Attack Treatments, Growing Adoption of SSRI Antidepressants and Availability of Favorable Reimbursement Policies for Medications and Therapies

Market Growth Drivers:
Rising Prevalence of Depression and Panic Attacks due to Unhealthier Lifestyles and Increasing Awareness about Panic Attack Treatments

Challenges:
Lack of Healthcare Infrastructure in Underdeveloped Countries and Complexities in International Drug Trades

Restraints:
Limited Patent Validity Timeline for Branded Depression Drugs and Adverse Side Effects from Panic Attack Drugs

Opportunities:
Surging Technological Advancements in Mental Health Drug Development and Robust Investments in Research and Development for ongoing Drug Discovery

Market Leaders and their expansionary development strategies
In December 2023, Calm partners with Samsung to integrate its panic attack management app into their line of smartwatches and wearables, enabling on-the-go support.
In October 2023: World Health Organization (WHO) releases a report highlighting the global burden of anxiety disorders, emphasizing the need for accessible and effective panic attack treatment options.
In 2004, the United States’ Food and Drug Administration (FDA) has mandated all the depression drug manufacturers to add a boxed warning to the labelling of all antidepressant medications. This labelling should warn about the rising risks of suicidal thinking or suicidal behaviour in children and adolescents taking antidepressants during initial treatment and with dose increases. Moreover, in 2007, FDA requested that the warning be extended to include young adults through age 24.

Key Target Audience
Metal Heath Treatment Providers, Anti-Depression Drug Manufacturers, Anti-Depression Drug Distributors and Traders, Medical Industry Associations, Government Agencies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Spontaneous Panic Attacks
  • Situationally Bound Panic Attacks
  • Situationally Predisposed Panic Attacks
By End Users
  • Adults
  • Children and Adolescents
  • Specific Populations

By Treatment Type
  • Therapy (Cognitive Behavioral Therapy (CBT), Exposure Therapy, Relaxation Techniques)
  • Medication (Antidepressants, Benzodiazepines)

By Indicators
  • MDD
  • OCD
  • Phobia

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Depression and Panic Attacks due to Unhealthier Lifestyles
      • 3.2.2. Increasing Awareness about Panic Attack Treatments
    • 3.3. Market Challenges
      • 3.3.1. Lack of Healthcare Infrastructure in Underdeveloped Countries
      • 3.3.2. Complexities in International Drug Trades
    • 3.4. Market Trends
      • 3.4.1. Emergence of Comparatively more Effective and Efficient Panic Attack Treatments
      • 3.4.2. Growing Adoption of SSRI Antidepressants
      • 3.4.3. Availability of Favorable Reimbursement Policies for Medications and Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Panic Attack Treatment, by Type, End Users, Treatment Type, Indicators and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Panic Attack Treatment (Value)
      • 5.2.1. Global Panic Attack Treatment by: Type (Value)
        • 5.2.1.1. Spontaneous Panic Attacks
        • 5.2.1.2. Situationally Bound Panic Attacks
        • 5.2.1.3. Situationally Predisposed Panic Attacks
      • 5.2.2. Global Panic Attack Treatment by: End Users (Value)
        • 5.2.2.1. Adults
        • 5.2.2.2. Children and Adolescents
        • 5.2.2.3. Specific Populations
      • 5.2.3. Global Panic Attack Treatment by: Treatment Type (Value)
        • 5.2.3.1. Therapy (Cognitive Behavioral Therapy (CBT), Exposure Therapy, Relaxation Techniques)
        • 5.2.3.2. Medication (Antidepressants, Benzodiazepines)
      • 5.2.4. Global Panic Attack Treatment by: Indicators (Value)
        • 5.2.4.1. MDD
        • 5.2.4.2. OCD
        • 5.2.4.3. Phobia
      • 5.2.5. Global Panic Attack Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Panic Attack Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi-Aventis (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbott Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F-Hoffmann-La Roche (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Shionogi and Company (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Panic Attack Treatment Sale, by Type, End Users, Treatment Type, Indicators and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Panic Attack Treatment (Value)
      • 7.2.1. Global Panic Attack Treatment by: Type (Value)
        • 7.2.1.1. Spontaneous Panic Attacks
        • 7.2.1.2. Situationally Bound Panic Attacks
        • 7.2.1.3. Situationally Predisposed Panic Attacks
      • 7.2.2. Global Panic Attack Treatment by: End Users (Value)
        • 7.2.2.1. Adults
        • 7.2.2.2. Children and Adolescents
        • 7.2.2.3. Specific Populations
      • 7.2.3. Global Panic Attack Treatment by: Treatment Type (Value)
        • 7.2.3.1. Therapy (Cognitive Behavioral Therapy (CBT), Exposure Therapy, Relaxation Techniques)
        • 7.2.3.2. Medication (Antidepressants, Benzodiazepines)
      • 7.2.4. Global Panic Attack Treatment by: Indicators (Value)
        • 7.2.4.1. MDD
        • 7.2.4.2. OCD
        • 7.2.4.3. Phobia
      • 7.2.5. Global Panic Attack Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Panic Attack Treatment: by Type(USD Million)
  • Table 2. Panic Attack Treatment Spontaneous Panic Attacks , by Region USD Million (2018-2023)
  • Table 3. Panic Attack Treatment Situationally Bound Panic Attacks , by Region USD Million (2018-2023)
  • Table 4. Panic Attack Treatment Situationally Predisposed Panic Attacks , by Region USD Million (2018-2023)
  • Table 5. Panic Attack Treatment: by End Users(USD Million)
  • Table 6. Panic Attack Treatment Adults , by Region USD Million (2018-2023)
  • Table 7. Panic Attack Treatment Children and Adolescents , by Region USD Million (2018-2023)
  • Table 8. Panic Attack Treatment Specific Populations , by Region USD Million (2018-2023)
  • Table 9. Panic Attack Treatment: by Treatment Type(USD Million)
  • Table 10. Panic Attack Treatment Therapy (Cognitive Behavioral Therapy (CBT), Exposure Therapy, Relaxation Techniques) , by Region USD Million (2018-2023)
  • Table 11. Panic Attack Treatment Medication (Antidepressants, Benzodiazepines) , by Region USD Million (2018-2023)
  • Table 12. Panic Attack Treatment: by Indicators(USD Million)
  • Table 13. Panic Attack Treatment MDD , by Region USD Million (2018-2023)
  • Table 14. Panic Attack Treatment OCD , by Region USD Million (2018-2023)
  • Table 15. Panic Attack Treatment Phobia , by Region USD Million (2018-2023)
  • Table 16. South America Panic Attack Treatment, by Country USD Million (2018-2023)
  • Table 17. South America Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 18. South America Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 19. South America Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 20. South America Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 21. Brazil Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 22. Brazil Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 23. Brazil Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 24. Brazil Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 25. Argentina Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 26. Argentina Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 27. Argentina Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 28. Argentina Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 29. Rest of South America Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 30. Rest of South America Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 31. Rest of South America Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 32. Rest of South America Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 33. Asia Pacific Panic Attack Treatment, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 35. Asia Pacific Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 36. Asia Pacific Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 37. Asia Pacific Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 38. China Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 39. China Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 40. China Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 41. China Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 42. Japan Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 43. Japan Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 44. Japan Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 45. Japan Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 46. India Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 47. India Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 48. India Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 49. India Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 50. South Korea Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 51. South Korea Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 52. South Korea Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 53. South Korea Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 54. Taiwan Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 55. Taiwan Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 56. Taiwan Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 57. Taiwan Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 58. Australia Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 59. Australia Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 60. Australia Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 61. Australia Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 66. Europe Panic Attack Treatment, by Country USD Million (2018-2023)
  • Table 67. Europe Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 68. Europe Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 69. Europe Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 70. Europe Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 71. Germany Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 72. Germany Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 73. Germany Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 74. Germany Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 75. France Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 76. France Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 77. France Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 78. France Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 79. Italy Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 80. Italy Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 81. Italy Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 82. Italy Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 83. United Kingdom Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 84. United Kingdom Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 85. United Kingdom Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 86. United Kingdom Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 87. Netherlands Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 88. Netherlands Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 89. Netherlands Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 90. Netherlands Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 91. Rest of Europe Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 92. Rest of Europe Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 93. Rest of Europe Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 94. Rest of Europe Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 95. MEA Panic Attack Treatment, by Country USD Million (2018-2023)
  • Table 96. MEA Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 97. MEA Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 98. MEA Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 99. MEA Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 100. Middle East Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 101. Middle East Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 102. Middle East Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 103. Middle East Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 104. Africa Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 105. Africa Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 106. Africa Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 107. Africa Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 108. North America Panic Attack Treatment, by Country USD Million (2018-2023)
  • Table 109. North America Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 110. North America Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 111. North America Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 112. North America Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 113. United States Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 114. United States Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 115. United States Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 116. United States Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 117. Canada Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 118. Canada Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 119. Canada Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 120. Canada Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 121. Mexico Panic Attack Treatment, by Type USD Million (2018-2023)
  • Table 122. Mexico Panic Attack Treatment, by End Users USD Million (2018-2023)
  • Table 123. Mexico Panic Attack Treatment, by Treatment Type USD Million (2018-2023)
  • Table 124. Mexico Panic Attack Treatment, by Indicators USD Million (2018-2023)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Panic Attack Treatment: by Type(USD Million)
  • Table 136. Panic Attack Treatment Spontaneous Panic Attacks , by Region USD Million (2024-2029)
  • Table 137. Panic Attack Treatment Situationally Bound Panic Attacks , by Region USD Million (2024-2029)
  • Table 138. Panic Attack Treatment Situationally Predisposed Panic Attacks , by Region USD Million (2024-2029)
  • Table 139. Panic Attack Treatment: by End Users(USD Million)
  • Table 140. Panic Attack Treatment Adults , by Region USD Million (2024-2029)
  • Table 141. Panic Attack Treatment Children and Adolescents , by Region USD Million (2024-2029)
  • Table 142. Panic Attack Treatment Specific Populations , by Region USD Million (2024-2029)
  • Table 143. Panic Attack Treatment: by Treatment Type(USD Million)
  • Table 144. Panic Attack Treatment Therapy (Cognitive Behavioral Therapy (CBT), Exposure Therapy, Relaxation Techniques) , by Region USD Million (2024-2029)
  • Table 145. Panic Attack Treatment Medication (Antidepressants, Benzodiazepines) , by Region USD Million (2024-2029)
  • Table 146. Panic Attack Treatment: by Indicators(USD Million)
  • Table 147. Panic Attack Treatment MDD , by Region USD Million (2024-2029)
  • Table 148. Panic Attack Treatment OCD , by Region USD Million (2024-2029)
  • Table 149. Panic Attack Treatment Phobia , by Region USD Million (2024-2029)
  • Table 150. South America Panic Attack Treatment, by Country USD Million (2024-2029)
  • Table 151. South America Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 152. South America Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 153. South America Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 154. South America Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 155. Brazil Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 156. Brazil Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 157. Brazil Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 158. Brazil Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 159. Argentina Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 160. Argentina Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 161. Argentina Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 162. Argentina Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 163. Rest of South America Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 164. Rest of South America Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 165. Rest of South America Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 166. Rest of South America Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 167. Asia Pacific Panic Attack Treatment, by Country USD Million (2024-2029)
  • Table 168. Asia Pacific Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 169. Asia Pacific Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 170. Asia Pacific Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 171. Asia Pacific Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 172. China Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 173. China Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 174. China Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 175. China Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 176. Japan Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 177. Japan Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 178. Japan Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 179. Japan Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 180. India Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 181. India Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 182. India Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 183. India Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 184. South Korea Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 185. South Korea Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 186. South Korea Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 187. South Korea Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 188. Taiwan Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 189. Taiwan Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 190. Taiwan Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 191. Taiwan Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 192. Australia Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 193. Australia Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 194. Australia Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 195. Australia Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 196. Rest of Asia-Pacific Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 197. Rest of Asia-Pacific Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 198. Rest of Asia-Pacific Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 199. Rest of Asia-Pacific Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 200. Europe Panic Attack Treatment, by Country USD Million (2024-2029)
  • Table 201. Europe Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 202. Europe Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 203. Europe Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 204. Europe Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 205. Germany Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 206. Germany Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 207. Germany Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 208. Germany Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 209. France Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 210. France Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 211. France Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 212. France Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 213. Italy Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 214. Italy Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 215. Italy Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 216. Italy Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 217. United Kingdom Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 218. United Kingdom Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 219. United Kingdom Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 220. United Kingdom Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 221. Netherlands Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 222. Netherlands Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 223. Netherlands Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 224. Netherlands Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 225. Rest of Europe Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 226. Rest of Europe Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 227. Rest of Europe Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 228. Rest of Europe Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 229. MEA Panic Attack Treatment, by Country USD Million (2024-2029)
  • Table 230. MEA Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 231. MEA Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 232. MEA Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 233. MEA Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 234. Middle East Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 235. Middle East Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 236. Middle East Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 237. Middle East Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 238. Africa Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 239. Africa Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 240. Africa Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 241. Africa Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 242. North America Panic Attack Treatment, by Country USD Million (2024-2029)
  • Table 243. North America Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 244. North America Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 245. North America Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 246. North America Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 247. United States Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 248. United States Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 249. United States Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 250. United States Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 251. Canada Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 252. Canada Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 253. Canada Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 254. Canada Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 255. Mexico Panic Attack Treatment, by Type USD Million (2024-2029)
  • Table 256. Mexico Panic Attack Treatment, by End Users USD Million (2024-2029)
  • Table 257. Mexico Panic Attack Treatment, by Treatment Type USD Million (2024-2029)
  • Table 258. Mexico Panic Attack Treatment, by Indicators USD Million (2024-2029)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Panic Attack Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Panic Attack Treatment: by End Users USD Million (2018-2023)
  • Figure 6. Global Panic Attack Treatment: by Treatment Type USD Million (2018-2023)
  • Figure 7. Global Panic Attack Treatment: by Indicators USD Million (2018-2023)
  • Figure 8. South America Panic Attack Treatment Share (%), by Country
  • Figure 9. Asia Pacific Panic Attack Treatment Share (%), by Country
  • Figure 10. Europe Panic Attack Treatment Share (%), by Country
  • Figure 11. MEA Panic Attack Treatment Share (%), by Country
  • Figure 12. North America Panic Attack Treatment Share (%), by Country
  • Figure 13. Global Panic Attack Treatment share by Players 2023 (%)
  • Figure 14. Global Panic Attack Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Panic Attack Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 19. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co. Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi-Aventis (France) Revenue: by Geography 2023
  • Figure 25. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 28. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 29. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 31. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 32. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 33. F-Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F-Hoffmann-La Roche (Switzerland) Revenue: by Geography 2023
  • Figure 35. Shionogi and Company (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Shionogi and Company (Japan) Revenue: by Geography 2023
  • Figure 37. Global Panic Attack Treatment: by Type USD Million (2024-2029)
  • Figure 38. Global Panic Attack Treatment: by End Users USD Million (2024-2029)
  • Figure 39. Global Panic Attack Treatment: by Treatment Type USD Million (2024-2029)
  • Figure 40. Global Panic Attack Treatment: by Indicators USD Million (2024-2029)
  • Figure 41. South America Panic Attack Treatment Share (%), by Country
  • Figure 42. Asia Pacific Panic Attack Treatment Share (%), by Country
  • Figure 43. Europe Panic Attack Treatment Share (%), by Country
  • Figure 44. MEA Panic Attack Treatment Share (%), by Country
  • Figure 45. North America Panic Attack Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • GlaxoSmithKline (United Kingdom)
  • Merck & Co. Inc. (United States)
  • Sanofi-Aventis (France)
  • AstraZeneca (United Kingdom)
  • Eli Lilly and Company (United States)
  • Johnson & Johnson (United States)
  • Abbott Laboratories (United States)
  • F-Hoffmann-La Roche (Switzerland)
  • Shionogi and Company (Japan)
Additional players considered in the study are as follows:
Forest Laboratories Inc. (United States) , H. Lundbeck A/S (Denmark) , Allergan Plc. (Ireland) , GlaxoSmithKline Plc. (United Kingdom) , Sumitomo Dainippon Pharma Co., Ltd. (Japan) , Bristol-Myers Squibb Company (United States) , Noven Pharmaceuticals, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 231 Pages 71 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Panic Attack Treatment Market Quantitative research analysis
Global Panic Attack Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer Inc. (United States), GlaxoSmithKline (United Kingdom), Merck & Co. Inc. (United States), Sanofi-Aventis (France), AstraZeneca (United Kingdom), Eli Lilly and Company (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), F-Hoffmann-La Roche (Switzerland) and Shionogi and Company (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Emergence of Comparatively more Effective and Efficient Panic Attack Treatments " is seen as one of major influencing trends for Panic Attack Treatment Market during projected period 2023-2029.
The Panic Attack Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Panic Attack Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Hirsutism-Treatment Comprehensive Study by Type (Idiopathic Hirsutism, Secondary Hirsutism, Others), Application (Hospitals and Clinics, Medical Research Laboratories, Academic Institutes), Treatment...
$ 3750
Skin Infection Comprehensive Study by Type (Bacterial Skin Infection, Viral Skin Infection, Fungal Skin Infection, Parasitic Skin Infection), by Treatment Type (Traditional Treatment, Basic Treatmen...
$ 3750
Wrist Joint Comprehensive Study by Type (Joint Replacement, Joint Repairment), End -users (Hospital, Clinic, Other), Joint (Ulnocarpal Joint, Radiocarpal Joint, Distal radioulnar Joint) Players and R...
$ 3500
Influenza Vaccines Comprehensive Study by Type (Paediatrics, Adolescence, Adults, Elderly), Application (Hospitals, Clinics, Others), Technology (Egg Based, Cell Culture, Recombinant), Vaccines (Fluz...
$ 3350
Paediatric Vaccine Comprehensive Study by Type (Pneumococcal, Varicella, Combinations, Poliovirus, Hepatitis , MMR , Pediatric Hormones , HIB, Allergy and Respiratory vaccines, Other Pediatric vaccin...
$ 3750
Microbiome Therapeutics Comprehensive Study by Type (FMT, Microbiome drugs), Indication (Type 2 diabetes, Obesity, C. difficile Infection, Primary Hyperoxyurea), Technology (Sequencing, Genomic Techn...
$ 3650